Grey Wolf Therapeutics has raised £10m ($12.9m) in Series A funding, allowing the UK start-up to proceed with its drug development program aimed at boosting a tumor's visibility to the body's immune system by increasing its neoantigen expression using small molecule modulators of endoplasmic reticulum aminopeptidases (ERAPs), key proteins in the antigen presentation pathway.
The visibility of a tumor to the immune system is one of the key determinants of whether a particular cancer...






